SOLIGENIX, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 29 EMMONS DRIVE, PRINCETON, NJ, 08540
Mailing Address 29 EMMONS DRIVE, PRINCETON, NJ, 08540
Phone 609-538-8200
Fiscal Year End 1231
EIN 411505029
Financial Overview
FY2025
-$8.27M
Net Income
$9.24M
Total Assets
$2.52M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 23, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | December 12, 2025 | View on SEC |
| 4 Insider stock transaction report | December 12, 2025 | View on SEC |
| 4 Insider stock transaction report | December 12, 2025 | View on SEC |
| 4 Insider stock transaction report | December 12, 2025 | View on SEC |
| 8-K Current report of material events | November 18, 2025 | View on SEC |
Annual Reports
10-K March 31, 2026
- Lead drug candidate HyBryte™ is in the critical FLASH2 clinical trial with results expected in mid-2026.
- Secured non-dilutive government funding from NIAID and BARDA for biodefense and infectious disease programs.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.